Contineum Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 31
- Market Cap
- $511.1M
- Website
- http://www.contineum-tx.com
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
Phase 1
Not yet recruiting
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary FibrosisMultiple SclerosisMultiple Sclerosis, MSMultiple Sclerosis, Primary ProgressiveMultiple Sclerosis, ProgressiveMultiple Sclerosis, Secondary ProgressiveHealthyHealthy Volunteers
- Interventions
- Drug: PIPE-791
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Contineum Therapeutics
- Target Recruit Count
- 28
- Registration Number
- NCT06683612
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
Phase 2
Active, not recruiting
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Drug: PIPE-307 Dose ADrug: PIPE-307 Dose BDrug: Placebo
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Contineum Therapeutics
- Target Recruit Count
- 168
- Registration Number
- NCT06083753
- Locations
- 🇺🇸
Xenosciences, Phoenix, Arizona, United States
🇺🇸Arizona Neuroscience Research, LLC, Phoenix, Arizona, United States
🇺🇸Alta Bates Summit Medical Center, Berkeley, California, United States
Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers
Phase 1
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: PlaceboDrug: PIPE-791
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Contineum Therapeutics
- Target Recruit Count
- 56
- Registration Number
- NCT05983939
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: PIPE-307
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Contineum Therapeutics
- Target Recruit Count
- 6
- Registration Number
- NCT04941781
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers
Phase 1
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Placebo oral tabletDrug: PIPE-307
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Contineum Therapeutics
- Target Recruit Count
- 70
- Registration Number
- NCT04725175
- Locations
- 🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia
Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss
Phase 1
Completed
- Conditions
- Sensorineural Hearing Loss
- Interventions
- Drug: PIPE-505Drug: Placebo
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Contineum Therapeutics
- Target Recruit Count
- 28
- Registration Number
- NCT04462198
- Locations
- 🇺🇸
Breathe Clear Institute, Torrance, California, United States
🇺🇸ENT and Allergy Associates of Florida, Boca Raton, Florida, United States
🇺🇸Charlotte Eye Ear Nose Throat Associates, Charlotte, North Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath